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Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clı́nic de Barcelona, Centro de
Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
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Abstract Somatic copy number alterations (CNAs) are a hallmark of cancer, but their role in
tumorigenesis and clinical relevance remain largely unclear. Here, we developed CNApp, a web-
based tool that allows a comprehensive exploration of CNAs by using purity-corrected segmented
data from multiple genomic platforms. CNApp generates genome-wide profiles, computes CNA
scores for broad, focal and global CNA burdens, and uses machine learning-based predictions to
classify samples. We applied CNApp to the TCGA pan-cancer dataset of 10,635 genomes showing
that CNAs classify cancer types according to their tissue-of-origin, and that each cancer type shows
specific ranges of broad and focal CNA scores. Moreover, CNApp reproduces recurrent CNAs in
hepatocellular carcinoma and predicts colon cancer molecular subtypes and microsatellite
instability based on broad CNA scores and discrete genomic imbalances. In summary, CNApp
facilitates CNA-driven research by providing a unique framework to identify relevant clinical
implications. CNApp is hosted at https://tools.idibaps.org/CNApp/.
Introduction
The presence of somatic copy number alterations (CNAs) is a ubiquitous feature in cancer. In fact,
the distribution of CNAs is sufficiently tissue-specific to distinguish tumor entities (Ried et al., 2012),
and allows the identification of tumors responsive to particular therapies (Cairncross et al., 2013;
Davoli et al., 2017). Moreover, high levels of CNAs, which result from chromosome instability, are
generally associated with high-grade tumors and poor prognosis (Hieronymus et al., 2018;
Sansregret et al., 2018; Smith and Sheltzer, 2018; Stopsack et al., 2019).
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Two main subtypes of CNAs can be discerned: broad CNAs, which are defined as whole-chromo-
some and chromosomal arm-level alterations, and focal CNAs, which are alterations of limited size
ranging from part of a chromosome-arm to few kilobases (Krijgsman et al., 2014; Zack et al.,
2013). Recently, it has been uncovered that while focal events mainly correlate with cell cycle and
proliferation markers, broad aberrations are mainly associated with immune evasion markers, sug-
gesting that tumor immune features might be determined by mechanisms related to overall gene
dosage imbalance rather than specific actionable genes (Buccitelli et al., 2017; Davoli et al., 2017;
Taylor et al., 2018). Furthermore, it has been shown that broad CNAs involving whole-chromosome
arms may confer high risk of lethal disease in prostate cancer (Stopsack et al., 2019). Nevertheless,
the precise role of CNAs in tumor initiation and progression, as well as their clinical relevance and
therapeutic implications in most cancer types remain still poorly understood.
Interpretation and visualization of CNAs is time-consuming and very often requires complex anal-
yses with clinical and molecular information. Well-established CNA algorithms, such as the gold-stan-
dard circular binary segmentation, define the genomic boundaries of copy number gains and losses
based on signal intensities or read depth obtained from array comparative genomic hybridization
and SNP-array or next-generation sequencing data, respectively (Olshen et al., 2004). However, the
tumor-derived genomic complexity may cause an under- or overestimation of CNAs. This complexity
is represented by tumor purity, tumor aneuploidy, and intratumor heterogeneity, which imply high
levels of subclonal alterations. Thus, recent segmentation methods improved the accuracy to identify
copy number segments in tumor samples either by considering the B allele frequency (BAF), such as
ExomeCNV (Sathirapongsasuti et al., 2011), Control-FREEC (Boeva et al., 2012) and SAAS-CNV
(Zhang and Hao, 2015), or through adjusting by sample purity and ploidy estimates, such as GAP
(Popova et al., 2009), ASCAT (Van Loo et al., 2010) and ABSOLUTE (Carter et al., 2012). How-
ever, the state-of-the-art computational approach for CNA analysis in cancer is GISTIC2.0
(Mermel et al., 2011), which is a gene-centered probabilistic method that enables to define the
boundaries of recurrent putative driver CNAs in large cohorts (Beroukhim et al., 2010). Neverthe-
less, despite ongoing progress on identifying CNAs, to our knowledge none of the existing software
packages is readily available for integrative analyses to unveil their biological and clinical
implications.
eLife digest In most cases, human cells contain two copies of each of their genes, yet
sometimes this can change, an effect called copy number alteration (CNA). Cancer is a genetic
disease and thus, studying the DNA from tumor samples is crucial to improving diagnosis and
choosing the right treatment. Most tumors contain cells with CNAs; however, the impact of CNAs in
cancer progression is poorly understood. CNAs can be studied by examining the genome of tumor
cells and finding which regions display an unusual number of copies. It may also be possible to
gather information about different cancer types by analyzing the CNAs in a tumor, but this approach
requires the analysis of large amounts of data.
To aid the analysis of CNAs in cancer cells, Franch-Expósito, Bassaganyas et al. have created an
online tool called CNApp, which is able to identify and count CNAs in genomic data and link them
to features associated with different cancers. The hope is that a better understanding of the effect
of CNAs in cancer could help better diagnose cancers, and improve outcomes for patients.
Potentially, this could also predict what type of treatment would work better for a specific tumor.
Besides, by using a machine-learning approach, the tool can also make predictions about specific
cancer subtypes in order to facilitate clinical decisions.
Franch-Expósito, Bassaganyas et al. tested CNApp using previously existing cancer data from 33
different cancer types to show how CNApp can help the interpretation of CNAs in cancer.
Moreover, CNApp can also use CNAs to identify different types of bowel (colorectal) cancer in a
way that could help doctors to make decisions about treatment. Together these findings show that
CNApp provides an adaptable and accessible research tool for the study of cancer genomics, which
could provide opportunities to inform medical procedures.
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To address this issue, we developed CNApp, the first open-source application to quantify CNAs
and integrate genomic profiles with molecular and clinical variables. CNApp is a web-based tool
that provides the user with high-quality interactive plots and statistical correlations between CNAs
and annotated variables in a fast and easy-to-explore interface. In particular, CNApp uses purity-cor-
rected genomic segmented data from multiple genomic platforms to redefine CNA profiles, to com-
pute CNA scores based on the number, length and amplitude of broad and focal genomic
alterations, to assess differentially altered genomic regions, and to perform machine learning-based
predictions to classify tumor samples. To exemplify the applicability and performance of CNApp, we
used publicly available segmented data from The Cancer Genome Atlas (TCGA) to (i) measure the
burden of global, broad, and focal CNAs as well as generate CNA profiles in a pan-cancer dataset
spanning 33 cancer types, (ii) identify cohort-based recurrent CNAs in hepatocellular carcinoma and
compare them with previously reported data, and (iii) assess predicting models for colon cancer
molecular subtypes and microsatellite instability status based on CNA scores and specific genomic
imbalances. CNApp is hosted at https://tools.idibaps.org/CNApp/ and the source code is freely




CNApp comprises three main sections: 1- Re-Seg and Score: re-segmentation, CNA scores compu-
tation, variable association and survival analysis, 2- Region profile: genome-wide CNA profiling,
CNA frequencies, correlation profiles and descriptive regions, and 3- Classifier model: machine
learning classification model predictions (Figure 1). Each of these sections and their key functions
are described below. The input file consists of a data frame with copy number segments provided
by any segmentation algorithm. Mandatory fields and column headers are sample name (ID), chro-
mosome (chr), start (loc.start) and end (loc.end) genomic positions, and the log2 ratio of the copy
number amplitude (seg.mean) for each segment. Section one incorporates the correction for tumor
purity (i.e. fraction of tumor cells in the sample) to measure the actual magnitude of CNAs. Thus,
when available, the input file will also include sample purity estimations (purity) and BAF values
(BAF), which correct the accuracy of CNA calls and provide copy number neutral loss-of-heterozy-
gosity (CN-LOH) events. Ploidy values, if known, might also be indicated as an independent variable.
Annotation of variables can be included in the input file (tagged in every segment from each sample)
or by uploading an additional file indicating new variables per sample.
Re-Seg and score: re-segmentation, CNA scores computation, variable
association and survival analysis
First, CNApp applies a re-segmentation approach to adjust for amplitude divergence due to techni-
cal variability and correct for estimated tumor purity. Default re-segmentation settings include mini-
mum segment length (100 Kbp), minimum amplitude (seg.mean) deviation from segment to zero
(0.16), maximum distance between segments (1 Mb), maximum amplitude (seg.mean) deviation
between segments (0.16), and maximum BAF deviation between segments (0.1). These parameters
can be customized by the user to better adjust the re-segmentation for each particular dataset. Re-
segmented data are then used to calculate the broad (BCS), focal (FCS) and global (GCS) CNA
scores, which provide three different quantifications of CNA levels for each sample. To compute
these scores, CNApp classifies and weights CNAs based on their length and amplitude. For each
sample, BCS is computed by considering broad (chromosome and arm-level) segment weights
according to the amplitude value. Likewise, calculation of FCS takes into account weighted focal
CNAs corrected by the amplitude and length of the segment. Finally, GCS is computed by consider-
ing the sum of normalized BCS and FCS, providing an overall assessment of the CNA burden.
To assess the reliability of CNA scores, we compared each score with the corresponding fraction
of altered genome using a TCGA pan-cancer set of 10,635 samples. Both BCS (ranging from 0 to 44)
and FCS (values ranging from 5 to 2466) highly correlated with the fraction of altered genome by
broad and focal copy number changes, respectively (Spearman’s rank correlation for BCS = 0.957
and for FCS = 0.938) (Figure 1—figure supplment 1A and B—source data 1). As expected, GCS
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Figure 1. CNApp workflow. The diagram depicts the overall processes performed by CNApp and indicates the output for each section.
The online version of this article includes the following source data and figure supplement(s) for figure 1:
Figure supplement 1. Spearman’s rank correlations between CNA scores and fractions of altered genome.
Figure 1 continued on next page
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(values ranged from  1.93 to 12.60) highly correlated with the fraction of altered genome affected
by both broad and focal CNAs (Spearman’s rank correlation for GCS = 0.963 (Figure 1—figure sup-
plment 1C—source data 1). Parametric and non-parametric statistical tests are used to establish
associations between CNA scores and annotated variables from the input file. Additionally, Kaplan-
Meier survival curves are computed using either CNA scores or additional variables.
Region profile: genome-wide CNA profiling
This section transforms segmented data (either re-segmented data from section one or original seg-
ments uploaded by the user) into genomic region profiles to allow sample-to-sample comparisons.
Different genomic windows can be selected to compute the genomic profiles (i.e. chromosome
arms, half-arms, cytobands, sub-cytobands or 40–1 Mb windows). All segments, or either only broad
or only focal can be selected for this analysis. Length-relative means are computed for each window
by considering amplitude values from those segments included in each specific window. Default cut-
offs for low-level copy number gains and losses (i.e., |0.2|) are used to infer CNA frequencies. Geno-
mic profiles are presented in genome-wide heatmaps to visualize general copy number patterns. Up
to six annotation tracks can be added and plotted simultaneously allowing visual comparison and
correlation between CNA profiles and different variables, including the CNA scores obtained in sec-
tion 1. CNA frequency summaries by genomic region and by sample are represented as stacked bar
plots. Correlation values and hierarchical clusters are optional.
Importantly, assessing differentially altered regions between sample groups might contribute to
discover genomic regions associated with annotated variables and thus unveil the biological signifi-
cance of specific CNAs. To do so, CNApp interrogates descriptive regions associated with any sam-
ple-specific annotation variable provided in the input file. Default statistical significance is set to
p-value lower than 0.1. However, p-value thresholds can be defined by the user and adjusted p-value
is optional. A heatmap plot allows the visualization and interpretation of which genomic regions are
differentially altered between sample groups. By selecting a region of interest, box plots and
stacked bar plots are generated comparing seg.mean values and alteration counts in Student’s t-test
and Fisher’s test tabs, respectively. Additionally, genes comprised in the selected genomic region
are indicated.
Classifier model: Machine learning classification model predictions
This section allows the user to generate machine learning-based classifier models by choosing a vari-
able to define sample groups and one or multiple classifier variables. To do so, CNApp incorporates
the randomForest R package (Liaw and Wiener, 2002). The model construction is performed 50-
times, in which training sets of 75% of samples are used in each permutation and the remaining 25%
are classified by applying the trained model. By default, annotation variables from the input file are
loaded and can be used either by defining sample groups or as a classifier. If Re-Seg and Score and/
or Region profile sections have been previously completed, the user can upload data from these sec-
tions (i.e. CNA scores and genomic regions). Predictions for the model performance are generated
and the global accuracy is computed along with sensitivity and specificity by group. Classifier models
can be useful to point out candidate clinical or molecular variables to classify sample subgroups.
Nevertheless, the output from the Classifier model would need to be further validated using alterna-
tive prediction algorithms and/or independent datasets. A summary of the data distribution and
plots for real and model-predicted groups are visualized. A table with prediction rates throughout
the 50-times iteration model and real tags by sample is displayed and can be downloaded.
Characterization of cancer types based on CNA scores
First, we evaluated the ability of CNApp to analyze and classify cancer types according to CNA
scores, and assessed whether CNApp was able to reproduce specific CNA patterns across different
cancer types. To do so, by using CNApp default parameters we obtained re-segmented data, CNA
scores and cancer-specific CNA profiles for 10,635 tumor samples spanning 33 cancer types from
Figure 1 continued
Figure supplement 1—source data 1. Data used for Spearman’s rank correlation analyses between CNA scores and fractions of altered genome.
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the TCGA pan-cancer dataset. The distribution of BCS, FCS and GCS confirmed the existence of dis-
tinct CNA burdens across cancer types (Figure 2A—source data 1). While cancer types such as
acute myeloid leukemia (LAML), thyroid carcinoma (THCA) or thymoma (THYM) showed low levels of
broad and focal events (GCS median values of  1.67 for LAML,  1.68 for THCA, and  1.52 for
THYM), uterine carcinosarcoma (UCS), ovarian cancer (OV) and lung squamous cell carcinoma (LUSC)
displayed high levels of both types of genomic imbalances (GCS median values of 2.55, 2.44, and
0.97 for UCS, OV, and LUSC, respectively). Some cancer types displayed a preference for either
broad or focal CNAs. For example, kidney chromophobe (KICH) tumors showed the highest levels of
broad events (median BCS value of 27), while focal CNAs in this cancer type were very low (median
FCS value of 49). In contrast, breast cancer (BRCA) samples displayed high FCS values (median FCS
value of 150), while BCS values were only intermediate (median BCS value of 7). Overall correlations
between CNA scores were assessed by computing Spearman’s rank test, obtaining values of 0.59
between BCS and FCS, 0.90 between BCS and GCS, and 0.85 between FCS and GCS. In addition,
we further assessed the correlation between BCS and FCS for each individual BCS value. While
tumors with low BCS displayed a positive correlation between broad and focal alterations, tumors
did not maintain such correlation in higher BCS values (Figure 2—figure supplement 1A and B).
This correlation between BCS and FCS is maintained across the 33 cancer types (Figure 2—figure
supplement 1C).
Subsequent analysis aimed at generating genome-wide patterns for each cancer type based on
chromosome-arm genomic windows and the overall corresponding frequencies. In agreement with
previous studies (Beroukhim et al., 2010), cancer type-specific patterns of genomic gains and losses
determined the tissue-of-origin (Figure 2B). Additionally, we found that chromosome arms altered
in more than 25% across all samples were 1q, 7 p, 7q, 8q and 20q for copy number gains, and 8 p
and 17 p for copy number losses. Conversely, chromosome arms affected by CNAs in less than 10%
of all cancer types included chromosome arms 2q and 19 p (Figure 2C). By using a subset of 20 out
of the 33 cancer types for which tumor type information was available, we asked CNApp to compute
the average arm-region for each cancer type to assess if they clustered according to their CNA pro-
files (Figure 2—figure supplement 2A). Our analysis showed that correlation values resulting from
Pearson’s test hierarchically clustered according to the tissue-of-origin from the tumor. Gastrointesti-
nal (colon, rectum, stomach and pancreatic), gynecological (ovarian and uterine) and squamous (cer-
vical, head and neck, and lung) cancers clustered together based on specific CNA profiles for each
group (Figure 2D). Intriguingly, correlation profiles using 5 Mb windows and only considering focal
alterations showed a very similar degree of clustering based on the tissue of origin (Figure 2—figure
supplement 2B&C).
Identification of recurrent CNAs in hepatocellular carcinoma:
Benchmark with other available tools
Next, we attempted to test the ability of CNApp to identify recurrent broad and focal CNAs in a
large cohort, and to assess the impact of the customizable parameters to describe CNA profiles. For
that reason, we chose to perform CNA analysis of 370 samples from TCGA corresponding to the
Liver Hepatocellular Carcinoma (LIHC) cohort. The pattern of recurrent broad and focal CNAs identi-
fied by GISTIC2.0 in the TCGA study (Ally et al., 2017) was similar to earlier reports, confirming the
suitability of this cohort and the consistent identification of a CNA profile for hepatocellular carci-
noma (HCC) (Chiang et al., 2008; Guichard et al., 2012; Schulze et al., 2015; Totoki et al., 2014;
Wang et al., 2013).
By applying the default parameters of CNApp to the LIHC dataset and selecting chromosome
arms as genomic regions to assess broad events, we consistently found copy number gains at 1q
(56%) and 8q (46%), and copy number losses at 8 p (62%) and 17 p (47%) as the most frequent alter-
ations (Figure 3A). These CNAs are the same as those identified by GISTIC2.0; however, frequencies
were slightly lower (Supplementary file 1). Similarly, GISTIC2.0 detected significant gains with rates
between 25–40% on eight additional chromosome-arms, including 5 p, 5q, 6 p, 20 p, 20q, 7 p, 7q,
and 17q, which were also identified by CNApp, but in 20–30% of the samples. Likewise, GISTIC2.0
detected significant broad deletions at a frequency between 20% and 40% on 18 additional chromo-
some-arms, of which 4q, 6q, 9 p, 13q, 16 p, and 16q losses were observed at frequencies  20% by
CNApp, and the rest of them displayed rates between 10% and 20%. Therefore, the identification of
CNAs in CNApp is very consistent with those described by GISTIC2.0. Differences in frequencies
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Figure 2. Analysis of the TCGA pan-cancer dataset and clustering by tumor type. CNApp outputs to characterize pan-cancer 10,635 samples including
33 TCGA cancer types. (A) Broad, Focal and Global CNA scores (BCS, FCS and GCS, respectively) distribution across the 33 cancer types (Figure 2—
source data 1). (B) Genome-wide chromosome arm CNA profile heatmap for 10,635 samples considering broad and focal events. Annotation tracks for
FCS, BCS and GCS are presented. (C) Arm regions frequencies as percentages relative to the TCGA pan-cancer dataset (red for gains and blue for
Figure 2 continued on next page
Franch-Expósito et al. eLife 2020;9:e50267. DOI: https://doi.org/10.7554/eLife.50267 7 of 22
Tools and resources Computational and Systems Biology Genetics and Genomics
Figure 2 continued
losses). (D) Heatmap plot showing 20 out of the 33 TCGA cancer type profile correlations, by Pearson’s method, hierarchically clustered by tissue of
origin. Gastrointestinal, gynecological and squamous cancers are clustering consistently in their respective groups.
The online version of this article includes the following source data and figure supplement(s) for figure 2:
Source data 1. Broad, Focal and Global CNA scores across the pan-cancer cohort.
Figure supplement 1. Correlation plots between FCS and BCS.
Figure supplement 2. Clustering analysis between cancer types.
Figure 3. Identification of recurrent broad and focal CNAs. Calculation of broad and focal CNA frequencies using several parameters in CNApp in
order to describe the genomic landscape of LIHC. (A) CNApp frequencies for chromosome arm regions using default cutoffs, corresponding to 2.3/1.7
copies for gains and losses, respectively. (B) CNApp frequencies for chromosome arm regions relaxing cutoffs to make them equivalent to those of
GISTIC2.0. (C) CNApp frequencies of focal events using default thresholds and sub-cytobands genomic regions. (D) Frequencies of focal events from
moderate- to high-amplitude levels using sub-cytobands genomic regions.
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. Genomic profiles corresponding to the LIHC dataset using alternative thresholds.
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might be expected due to the lower copy number amplitude thresholds used by GISTIC2.0 in com-
parison with CNApp default cutoffs (|0.1| vs. |0.2|, corresponding to ~2.14/1.8 copies vs. 2.3/1.7 cop-
ies, respectively). Indeed, previous reports analyzing CNAs in other HCC cohorts and using greater
copy number thresholds, showed frequencies of alterations much more similar to those estimated by
CNApp (Chiang et al., 2008; Guichard et al., 2012; Schulze et al., 2015; Wang et al., 2013). To
assess the impact of modifying CNApp amplitude thresholds, we analyze the same dataset dropping
the cutoff to |0.1|. By doing so, the overall number of broad CNAs increased, reaching frequency val-
ues similar or even higher than those reported by GISTIC2.0 (Figure 3B and Supplementary file 1).
Of note, such drop from |0.2| to |0.1| might result in the identification of subclonal genomic imbalan-
ces, which are very frequent in tumor samples (McGranahan and Swanton, 2017), and it would also
be of utility to compensate for low tumor purities. To evaluate the impact of other customizable
parameters of CNApp to the results, we also tested whether the identification of broad events was
affected by: (i) the relative length to classify a segment as arm-level alteration, and (ii) the re-seg-
mentation provided by CNApp. As expected, increasing the percentage of chromosome arm
required to classify a CNA segment as arm-level (from 50% to70%) or skipping the re-segmenta-
tion step led to an underestimation of some broad events, whereas decreasing the percentage of
chromosome arm (from 50% to40%) resulted in the opposite (Figure 3—figure supplement 1A–
C and Supplementary file 1).
As far as focal CNAs are concerned, CNApp and GISTIC2.0 use different strategies to quantify
their recurrence. Therefore, the comparison between the two methods was evaluated in a more indi-
rect manner. GISTIC2.0 generates minimal common regions (also known as ‘peaks’) that are likely to
be altered at high frequencies in the cohort, which are scored using a Q-value and may present a
wide variety of genomic lengths (Mermel et al., 2011). Instead, CNApp allows dividing the genome
in windows of different sizes, calculating average copy number amplitudes for all segments included
within each window. We reasoned that considering the length of GISTIC2.0 reported ‘peaks’,
CNApp might also be capable of identifying recurrent focal altered regions by dividing the genome
in smaller windows. To test our hypothesis, we asked CNApp to calculate the frequency of focal
gains and losses by dividing the genome by sub-cytobands. As a result, CNApp consistently local-
ized the most frequently altered sub-cytobands, including gains at 1q21.3 (25%), 8q24.21 (17%,
MYC), 5p15.33 (13%, TERT), 11q13.3 (12%, CCND1/FGF19) and 6p21.1 (11%, VEGFA), and losses at
13q14.2 (20%, RB1), 1p36.11 (18%, ARID1A), 4q35.1 (17%, IRF2) and 9p21.3 (14%, CDKN2A), which
are in agreement with previous studies in HCC (Figure 3C and Supplementary file 2) (Chiang et al.,
2008; Guichard et al., 2012; Schulze et al., 2015; Wang et al., 2013). Compared to GISTIC2.0,
CNApp reported 14 of the 27 significant amplifications and 14 of the 34 significant deletions at
rates > 10%, and the remaining alterations displaying rates between 4–10% (Supplementary file 3)
(Wang et al., 2013). Most importantly, regions with the highest frequency detected by CNApp
showed a good match with lowest GISTIC2.0 Q-residual values, indicating that the most significant
‘peaks’ identified by GISTIC2.0 were actually included in the most recurrently altered sub-cytobands
reported by CNApp.
Recurrent focal alterations occur at lower frequencies than broad events (Beroukhim et al.,
2010). Previous studies describing the genomic landscape of HCC mostly focused on focal high-
amplitude CNAs (>3 copies for gains and <1.3 copies for losses), thus reporting lower frequencies
than those estimated by CNApp using default thresholds (Chiang et al., 2008; Guichard et al.,
2012; Schulze et al., 2015). In our analysis, excluding the low-level alterations and evaluating only
the moderate and high-amplitude events (3 and1 copies), amplifications reached maximum rates
of 11%, whereas high-level losses only reached ~2% (Figure 3D and Supplementary file 2). Top
recurrent focal gains involved sub-cytobands 1q21.3 (11%), 8q24.21 (11%, MYC), 11q13.3 (7%,
CCND1/FGF19), and 5p15.33 (5%, TERT). Recurrent losses estimated at ~2% of the samples
included 13q14.2 (RB1), 9p21.3 (CDKN2A), 4q35.1 (IRF2), and 8p23.1. Although slight discrepancies
between frequencies might be explained by minimal variability in the copy number threshold,
CNApp results are highly consistent with previous reports (Chiang et al., 2008; Guichard et al.,
2012; Schulze et al., 2015).
In order to assess genomic differences between independent sample sets, CNApp determines
significance based on regression analysis and statistical tests such as Student’s t-test or Fisher’s
exact test, which allow association of genomic regions based on the seg.mean value or the presence
of alterations with specific samples, respectively. To test the suitability of our method, we analyzed a
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subset of 100 randomly selected samples from the LIHC (n = 50) and COAD (n = 50) TCGA cohorts
and we compared our results with those obtained by the recently published tool CoNVaQ
(Larsen et al., 2018). Fourteen CNAs (5 gains and 9 losses) showing significant differences between
COAD and LIHC were identified by CoNVaQ with a Q < 0.05. The lengths of these CNAs ranged
from 38 to 133 Mb, with an average of 67 Mb, suggesting that they were mainly broad events. Con-
sequently, in CNApp, we selected genomic windows corresponding to chromosome arms, and used
the default CNA cut-offs (i.e. |0.2|) and maximum number of base pairs allowed for merging adjacent
segments (i.e. 1,000,000 bp) for comparison. By doing so, 9 out of 14 events identified by CoNVaQ
were also detected by CNApp with an adjusted p<0.05 (Fisher’s exact test). For the remaining five
events, four of them were found with an adjusted p=0.06–0.1, thus suggesting a good correlation
between CNApp and CoNVaQ when considering broad CNAs.
Classification of colon cancer according to CNA scores and genomic
regions
A proposed taxonomy of colorectal cancer (CRC) includes four consensus molecular subtypes (CMS),
mainly based on differences in gene expression signatures (Guinney et al., 2015). Briefly, CMS1
includes the majority of hypermutated tumors showing microsatellite instability (MSI), high CpG
island methylator phenotype (CIMP), and low levels of CNAs; CMS2 and CMS4 typically comprise
microsatellite stable (MSS) tumors with high levels of CNAs; and finally, mixed MSI status and low
levels of CNAs and CIMP are associated with CMS3 tumors. A representative cohort of 309 colon
cancers from the TCGA Colon Adenocarcinoma (COAD) cohort (Cancer et al., 2012) with known
CMS classification (CMS1, N = 64; CMS2 N = 112; CMS3 N = 51; CMS4 N = 82) and MSI status
(MSI, N = 72; MSS, N = 225) was analyzed by using CNApp. In agreement with Guinney and col-
leagues, survival curves generated by CNApp indicated that CMS1 patients after relapse showed
the worst survival rates as compared to CMS2 patients (Figure 4—figure supplement 1A)
(Guinney et al., 2015). Next, we asked CNApp to perform the re-segmentation step using the
default copy number thresholds and excluding segments smaller than 500 Kbp to avoid technical
background noise. Then, broad CNAs were considered to generate genomic region profiles using
chromosome-arm windows. As expected, the CNA frequency plot displayed the most commonly
altered genomic regions in sporadic CRC (Figure 4—figure supplement 1B) (Camps et al., 2008;
Cancer et al., 2012; Meijer et al., 1998; Nakao et al., 2004; Ried et al., 1996). Most frequently
altered chromosome arms included gains of 7 p, 7q, 8q, 13q, 20 p, and 20q, and losses of 8 p, 17 p,
18 p, and 18q, occurring in more than 30% of the samples (Figure 4A). On the other hand, focal
CNA patterns were obtained by generating genomic profiles by sub-cytobands. Of note, five out of
six losses and five out of 18 gains were also identified by GISTIC2.0 in the COAD TCGA cohort
(Cancer et al., 2012).
Subsequently, we performed integrative analysis of genomic imbalances, CMS groups, and CNA
scores. By using CNApp, we assessed whether CNA scores were able to classify colon cancer sam-
ples according to their CMS. While BCS established significant differences between CMS paired
comparisons (p0.0001, Student’s t-test), FCS poorly discerned CMS1 from three and CMS2 from 4
(Figure 4B—source data 1 and Figure 4—figure supplement 1C—source data 1). Thus, we rea-
soned that broad CNAs rather than focal were able to better discriminate between different CMS
groups. In fact, the distribution of CMS groups based on BCS resembled the distribution of somatic
CNA counts defined by GISTIC2.0 (Guinney et al., 2015).
Next, we integrated the BCS and the CMS groups with the microsatellite status. Our results
showed an average BCS of 1.51 ± 2.11 and 10.25 ± 5.92 for MSI (N = 72) and MSS (N = 225) tumors,
respectively. By applying CNApp’s Classifier model to the COAD cohort, we chose MSI and MSS
status (72 MSI and 225 MSS samples). Global accuracy in average for the 50-permutation in the Ran-
domForest model was 82.2%. Re-classification of MSI and MSS samples was successfully achieved
and distribution of BCS values across MSI and MSS-predicted samples is plotted in Figure 4—figure
supplement 1D. Intersection between predicted MSI and MSS groups resulted in a BCS value of
4.75, and further analysis by ROC curve implementation between MSI and MSS groups with BCS val-
ues as classifier proxy resulted in an AUC of 0.917. In addition, the intersection between sensitivity
and specificity from ROC analysis resulted in a BCS value of 3.5 (Figure 4—figure supplement 1E).
Altogether, we decided to implement a BCS value of 4 as a threshold to re-classify samples accord-
ing to their MSI status. In order to validate that a BCS value of 4 was able to predict microsatellite
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Figure 4. Genomic characterization of colon cancer according to the CMS classification. (A) Arm-region frequencies of 309 colon cancer samples using
CNApp default thresholds for CNAs. (B) BCS distribution by CMS sample groups (Figure 4—source data 1). FCS distribution by CMS sample groups is
presented in Figure 4—figure supplement 1C. Wilcoxon rank-sum test significance is shown as p-value0.001 (***); p-value0.01 (**); p-value0.05
(*); p-value>0.05 (ns). (C) Number of gained and lost chromosome arms for each sample distributed according to the BCS values. Note that a cutoff at
four is indicated with a black line. Annotation tracks for microsatellite instability (msi), BRAF mutated samples (braf_mut), CMS groups (cms_label), FCS
Figure 4 continued on next page
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status, we used a completely independent CRC cohort (Berg et al., 2019). The validation dataset
consisted of segmented data from 147 samples with known microsatellite status and CMS annota-
tion (MSI, N = 28; MSS, N = 119; CMS1, N = 27; CMS2, N = 61; CMS3, N = 29; CMS4, N = 30). We
then ran CNApp to obtain BCS values for each sample and applied our BCS of 4 as the threshold to
re-classify samples (i.e. MSI if BCS 4, and MSS if BCS >4) using the Classifier model. By doing so,
we obtained a global accuracy of 81%, which is similar to the accuracy obtained in the COAD data-
set (82.2%), thus suggesting that a BCS equal to four might be considered as a universal threshold
to determine microsatellite status in CRC.
Applying the cutoff of 4 to the COAD cohort, 186 out of 225 (83%) of MSS tumors showed BCS
values greater than 4 (Figure 4C). In contrast, 39 (17%) MSS tumors showed a BCS of 4 or lower,
corresponding to three CMS1, six CMS2, 18 CMS3 and 12 CMS4 tumors, further demonstrating the
existence of MSS tumors with a very low CNA burden. On the other hand, seven MSI tumors showed
BCS higher than 4. Among them, five samples displayed genomic imbalances typically associated
with the CRC canonical pathway, including a focal amplification of MYC, unveiling tumors with co-
occurrence of MSI and extensive genomic alterations (Trautmann et al., 2006). Our dataset com-
prised nine out of 51 CMS3 tumors with MSI. Intriguingly, two of them showed focal deletions on
chromosome two involving MSH2 and MSH6, suggesting the inactivation of these mismatch repair
genes through a focal genomic imbalance. In fact, 46% of CMS3 MSS tumors showed BCS below 4,
in agreement with the finding that CMS3 tumors display low levels of somatic CNAs.
Moreover, CNApp enabled the identification of possible sample misclassifications by integrating
CMS annotation and BRAF-mutated sample status. As expected, CMS1 cases were enriched for
BRAF mutation, although two CMS4 samples also showed mutations in BRAF. One of these samples
showed a BCS of 11, displaying canonical CNAs. In contrast, the other CMS4 BRAF-mutated sample
showed MSI and a BCS of 0, similar features as CMS1. Likewise, four BRAF-wt samples, classified
within the CMS4 group, displayed MSI and a BCS of 0, thus being candidates to be labeled as
CMS1 based on the levels of CNAs (Figure 4D). These disparities are of utmost importance since
recent studies reported that high copy number alterations correlate with reduced response to immu-
notherapy (Davoli et al., 2017). Importantly, it has been suggested that MSI status might be predic-
tive of positive immune checkpoint blockade response in advanced CRC, probably due to the low
levels of CNA usually presented by MSI tumors (Le et al., 2015).
We then asked CNApp to compare differentially represented genomic regions between all CMS
groups based on a Student’s t-test or Fisher’s test with adjusted p-value. By applying a Student’s
t-test, we observed that CMS1 resembled CMS3, except for the gain of chromosome seven and the
loss of 18q, which were regions commonly altered in CMS3 samples with BCS above 4 (adjusted
p0.001, Student’s t-test) (Figure 4E). Even though only subtle CNA differences between CMS2
and CMS4 were identified, the loss of 14q was significantly more detected in CMS2 (42%) than in
CMS4 (17.1%) (adjusted p0.005, Student’s t-test). The gain of 12q was more frequently associated
with CMS1 than CMS2 (adjusted p0.005, Student’s t-test), in agreement with previous studies
reporting that the gain of chromosome 12 is associated with microsatellite unstable tumors
(Figure 4E) (Trautmann et al., 2006). Intriguingly, the gain of the chromosome arm 20q alone mim-
icked the distribution of somatic CNAs defined by GISTIC2.0 across consensus subtype samples (Fig-
ure 4—figure supplement 1F) (Guinney et al., 2015).
Finally, applying machine learning-based prediction models to classify samples by the most dis-
criminative descriptive regions across CMS groups (i.e. 13q, 17 p, 18, and 20q), CNApp reached
Figure 4 continued
and BCS are displayed. (D) Genome-wide profiling by chromosome arms distributed according to the CMS group. Annotation tracks for microsatellite
instability (msi), BRAF mutated samples (braf_mut), CMS groups (cms_label), FCS and BCS are displayed. Sample-to-sample correlation heatmap plot
by Pearson’s method is shown below. (E) Differentially altered chromosome arm regions between CMS groups (CMS1, CMS2, CMS3 and CMS4).
Heatmap plot displaying the significance between CMS groups paired comparisons. Student’s T-test was applied and multiple testing correction by BH
method was used to assess differences in chromosome arm values between groups. Adjusted p-values are displayed.
The online version of this article includes the following source data and figure supplement(s) for figure 4:
Source data 1. BCS by CMS sample group.
Figure supplement 1. Genomic analysis of the COAD cohort.
Figure supplement 1—source data 1. FCS by CMS sample group.
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55% of accuracy to correctly predict CMS. In fact, the occurrence of these genomic alterations was
able to differentiate CMS2 from CMS4 with an accuracy of 70%, and CMS1 from CMS3 with a 72.3%
accuracy. As expected, this set of genomic alterations distinguished CMS1 from CMS2 samples with
an accuracy of 95%.
Discussion
Here, we present CNApp, a web-based computational tool that provides a unique framework to
comprehensively analyze and integrate CNAs associated with molecular and clinical variables, assist-
ing data-driven research in the biomedical context. Although CNApp has been developed using seg-
mented genomic copy number data obtained from SNP-arrays, the software is also able to
accommodate segmented data from any next-generation sequencing platform.
CNApp transforms segmented data into genomic profiles, allowing sample-by-sample compari-
son and the assessment of differentially altered genomic regions, which can then be selected by the
user to assess classifier variables by computing machine learning-based models. Importantly, besides
identifying the impact of specific CNAs, CNApp provides the unique opportunity to establish associ-
ations between the burden of genomic alterations and any clinical or molecular variable. To do so,
CNApp calculates CNA scores, a quantification of the broad (BCS), focal (FCS) and global (GCS) lev-
els of genomic imbalances for each individual sample. The fact that high levels of aneuploidy may
correlate with tumor immune evasion markers and that CNA burdens may be an independent prog-
nostic factor for cancer-specific lethality in some cancers exemplifies the potential association of
CNA scores with clinical outcomes (Buccitelli et al., 2017; Davoli et al., 2017; Hieronymus et al.,
2018; Taylor et al., 2018). To note, CNA scores are calculated after an optional process of re-seg-
mentation that enables to redefine CNA boundaries and to adjust sample-specific copy number
thresholds by correcting for tumor purity estimates.
In agreement with recently reported findings (Beroukhim et al., 2010; Hoadley et al., 2018;
Taylor et al., 2018), CNApp was benchmarked by analyzing 10,635 samples spanning 33 cancer
types from the TCGA pan-cancer dataset, and was able to cluster major tumor types according to
CNA patterns. Moreover, the software successfully reproduced the well-characterized genomic pro-
file of HCC and CRC, considering both broad and focal events, demonstrating the reliability of
CNApp in identifying regions encompassing the most recurrent CNAs (Ally et al., 2017;
Cancer et al., 2012).
Finally, applying CNApp to the TCGA colon cancer sample set, for which MSI status and CMS
classification was well annotated, we determined that a BCS value of 4 discriminates MSI from MSS
tumors with high accuracy, reinforcing the utmost significance of quantifying the CNA burdens.
Most importantly, due to the inverse correlation between MSI and aneuploidy in CRC, our results
suggest that this BCS value could be established as a cutoff to define the edge between low and
high aneuploid tumors. In fact, while high aneuploid tumors show poor response to immunotherapy,
it has been suggested that CMS1 microsatellite unstable tumors are likely to show a positive
response to immune checkpoints inhibitors (Kalyan et al., 2018; Le et al., 2015). However, BCS was
not associated with overall survival in patients after relapse (data not shown). Moreover, specific
genomic regions defined by CNApp contributed to classify the CMS groups, confirming the func-
tional importance of specific genomic imbalances in the pathogenesis of this disease and providing
insights into the classification of CRC based on CNA profiles.
In summary, although our results ought to be further validated in independent cohorts, here we
show that CNApp enables not only the fundamental analysis of CNA profiles, but also the functional
understanding of CNAs in the context of clinical outcome and their potential use as biomarkers, thus
becoming an asset to the cancer genomics community.
Materials and methods
Data availability
Pan-cancer cohort and clinical annotation
Affymetrix SNP6.0 array copy number segmented data (Level 3) from 10,635 samples spanning 33
cancer types from TCGA pan-cancer dataset were downloaded from the Genomic Data Commons
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Data Portal (GDC Data Portal, RRID:SCR_014514) (Grossman et al., 2016). This dataset included
the 370 Liver Cancer-Hepatocellular Carcinoma (LIHC) samples used for the analysis of recurrent
CNAs and the subset of 309 samples from Colon Adenocarcinoma (COAD) for which the colorectal
cancer consensus molecular subtype (CMS) was known (Guinney et al., 2015).
Clinical annotation for the 309 COAD samples was retrieved by using TCGAbiolinks R package
(TCGAbiolinks, RRID:SCR_017683) in order to extract survival information for each sample
(Colaprico et al., 2016).
GISTIC data from TCGA: LIHC cohort
GISTIC 2.0.22 (Ally et al., 2017) copy number results from 370 LIHC samples included in the TCGA
(The Cancer Genome Atlas, RRID:SCR_003193), were downloaded from the Broad Institute GDAC
Firehose (https://gdac.broadinstitute.org/). Parameters used for the analysis are detailed in the same
GDAC repository. Specifically, parameters conditioning the definition of the CNAs and of interest
for our comparison were publicly reported with the following values: amplification and deletion
thresholds: 0.1; broad length cutoff: 0.7; joint segment size: 4.
Software and tool availability
CNApp can be accessed at https://tools.idibaps.org/CNApp/. It was developed using Shiny R pack-
age (version 1.1.0), from R-Studio (Shiny, RRID:SCR_001626) (Chang et al., 2018). The tool was
applied and benchmarked while using R version 3.4.2 (2017-09-28) – ‘Short Summer’. List of pack-
ages, libraries and base coded are freely available at GitHub, and instructions for local installation
are also specified.
Baseline adjustment of seg.mean values by sample purity
The amount of non-aberrant cell admixture may differ between cancer samples, necessitating sepa-
rate adjustment of copy number thresholds for each assayed sample. To homogenize the analysis,
purity estimations are used by CNApp to apply a baseline adjustment of the seg.means before the
subsequent CNA calling by CNA amplitude thresholds. This adjustment allows for subsequent sam-
ple-to-sample comparison. Seg.mean values (n) by sample (x), when purity (r) available, are re-com-
puted into new seg.mean values (N) as follows:
N xð Þ ¼ 2n xð Þþ r xð Þ 1ð Þ
When purity is not provided, 100% purity (r = 1) is assumed. Minimal purity accepted is 40%
(r = 0.4), setting to 40% all purities below. Threshold of 40% also sets the negative capping value (C)








Segments resulting from re-segmentation (or original segments from input file when re-segmenta-
tion is skipped) are classified in chromosomal, arm-level and focal events by considering the relative
length of each segment to the whole-chromosome or chromosome arm. Using default parameters,
segments are tagged as chromosomal when 90% or more of the chromosome is affected; as arm-
level when 50% or more of the chromosome arm is affected; and as focal when affecting less than
50% of the chromosome arm. Percentages for relative lengths are customizable.
Broad (chromosomal and arm-level) and focal alterations are then weighted according to their
amplitude values (seg.mean) and taking into account copy number amplitude ranges defined by
CNA calling thresholds. Default amplitude thresholds to define these ranges, CNA levels and their
corresponding absolute copy number are presented in Table 1.
In order to take into account the relative chromosome length from each segment when FCS is
computed, coverage punctuation for focal events is implemented as specified in Table 2.
Broad CNA Score (BCS): for a total N of broad events in a sample (x), it equals to the summation
of segments weights (A) in that corresponding sample and being i the corresponding segment:
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Focal CNA Score (FCS): same as in BCS, with an additional pondering value L included to the
summation, which captures the relative size of the chromosome-arm coverage of each focal CNA):





Global CNA Score (GCS): for a sample x, it is calculated as the summation of normalized BCS and
FCS values, where meanBCS and meanFCS stand for mean values of BCS and FCS from total sam-
ples, respectively, and sdBCS and sdFCS stand for standard deviation values of BCS and FCS from
total samples, respectively:
normBCS xð Þ ¼
BCS xð Þ meanBCS
sdBCS
normFCS xð Þ ¼
FCS xð Þ meanFCS
sdFCS
GCS xð Þ ¼ normBCS xð Þþ normFCS xð Þ
Correlation between CNA scores and the fraction of genome altered
Correlation between broad, focal and global CNA scores (BCS, FCS and GCS, respectively) was
assessed by computing Spearman’s rho statistic. The TCGA pan-cancer dataset including 10,635
samples spanning 33 cancer types was used to perform these associations. This data was down-
loaded from the Genomic Data Commons Data Portal (GDC Data Portal, RRID:SCR_014514)
(Grossman et al., 2016).
To evaluate the applicability of the CNA scores when it comes to sample CNA level assessment,
we performed correlation analyses between CNA scores and the altered genome fraction. BCS and
FCS were specifically correlated to the altered genome fraction by broad (i.e., chromosomal and
arm-level events) and focal alterations, respectively. To do so, we applied the re-segmentation pro-
cedure and CNA scores computation on a TCGA dataset comprised by 10,635 primary tumors from
33 TCGA projects analyzed by Affymetrix 6.0 SNP-array and DNACopy (DNAcopy, RRID:SCR_
012560) (Venkatraman and Olshen, 2007). Global altered genome fraction (altFract) was computed,
Table 1. Corresponding weights (A) for each threshold, CNA level and its absolute copy number.
Thresholds
(Log2ratio values) CNA level Copy number Weights (A)
1 High-level gain 4 copies 3
0.58 Medium-level gain [3–4) copies 2
0.2 Low-level gain [2.3–3] copies 1
 0.2 Low-level loss (1–1.7] copies 1
-1 Medium-level loss (0.6–1] copies 2
 1.74 High-level loss 0.6 copies 3
[ 0.2–0.2] Copy-neutral loss-of-heterozygosity (CN-LOH) [1.7–2.3] copies
BAF  0.25
2
Table 2. Coverage punctuation (L) for focal events.
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for each sample (x), by the summation of all copy number events lengths (l) and divided by total
length of human genome (hgLength).






Altered genome fractions for broad and focal events were computed, for each sample (x), by the
summation of broad and focal alterations lengths (l), respectively, and divided by total length of
human genome (hgLength).












Correlation tests were performed by applying Spearman’s rho statistic to estimate a rank-based
measure of association.
Associations between CNA scores and annotated variables
Annotated variables from input file are statistically associated with CNA scores computed by CNApp
in Re-Seg and Score section. Different association tests are applied according to variable class (i.e.
categoric or numerical), as described in Table 3. Both parametric and non-parametric tests are com-
puted to present p-values in order to assess statistical significance for each association.
Survival analysis
Survival analysis by Kaplan-Meier was performed using survival and survminer R packages (CRAN,
RRID:SCR_003005).
Genomic region profiles computation
Region profiling section allows genome segmentation analysis by user-selected windows (i.e. arms,
half-arms, cytobands, sub-cytobands, and 40 Mb till 1 Mb). In order to do that, windows files were
generated for each option and genome build (hg19 and hg38). Cytobands file cytoBand.txt from
UCSC page and for both genome builds was used as mold to compute regions (Tyner et al., 2017).
Segmented samples are transformed into genome region profiles using genomic windows
selected by user. Segments from each sample are consulted to assess whether or not overlap with
the window region. Thus, window-means (W) are computed for each genomic window by collecting
segments (t) overlapping with window-region (i). Segments with loc.start or loc.end position falling
within the region are collected, as well as those segments embedding the entire region. At this
point, the summation of each segment-mean (S) corrected by the relative window-length (L) affected
by the segment length (l) is performed:








Potential descriptive regions between groups defined by the annotated variables provided in the
input file can be studied and p-values are presented to evaluate significance in differentially altered
regions between those groups. The alterations can be considered as (1) numerical continuous (seg.
mean values) and (2) categorical variables (gains, losses and non-altered). In the first case, to assess
statistical significance between groups Student’s T-test is applied, whereas in the second situation
the significance is assessed by applying the Fisher’s exact test. False discovery rate (FDR) adjustment
is performed using the Benjamini-Hochberg (BH) procedure in both cases and corrected p-values
(Adj.p-value) or non-corrected p-values (p-values) are displayed by user selection.
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Clustering analysis
Correlation and clustering methods can be applied into heatmap plots in CNApp Region profile sec-
tion. Accepted correlation methods are Pearson’s, Spearman’s and Kendall’s tests. Hierarchical clus-
ter analysis is applied when clusters are computed in heatmaps.
Machine learning-based classifier models
We used the randomForest R package (RandomForest Package in R, RRID:SCR_015718) (Liaw and
Wiener, 2002) to compute machine learning classifier models. Variables to define sample groups
must be selected, as well as at least one classifier variable. Model construction is performed 50-times
and training set is changed by iteration. In order to compute model and select training set, multiple
steps and conditions have to be accomplished:
i. Total N samples divided by G groups depicted by group-defining variable must be higher





ii. If condition above is not accomplished, then P is set to 75% of n:
if P n then P¼ n  0:75
iii. P term must be higher than one, and N must be equal or higher than 20:
P>1 or N  20
iv. Classifier variables, when categorical, shall not have higher number of tags (Z) than groups
defined (G) by group-defining variable:
Z<G
v. Training set (T) is computed and merged for each group (g) from groups (G) defined by
group variable, extracting P samples from g as follows:





After model computation, contingency matrix with prediction and reference values by group is
created to compute accuracy, specificity and sensitivity by group.
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. Supplementary file 1. Comparative analysis of broad CNA frequencies between CNApp and GIS-
TIC2.0. This table displays the comparison between GISTIC and CNApp in terms of broad CNAs by
dividing the genome in chromosome arms. First set of columns shows GISTIC frequencies of amplifi-
cations (Amp_Freq) and deletions (Del_Freq) with a threshold set at |0.1|. Remaining columns include
results from CNApp, using different parameters. CNApp default CNA thresholds are |0.2|, whereas
CNApp relaxed CNA thresholds were dropped to |0.1|. CNApp resegmentation parameters (reseg)
are indicated accordingly. (XLSX 15 KB)
. Supplementary file 2. Frequencies of focal alterations identified by CNApp using minor sub-cyto-
bands genomic windows. First three columns (No CNA, CN Gain, CN Loss) display the number of
samples with no CNA, gains or losses at each minor sub-cytoband using CNApp default thresholds.
Next columns (‘low-level’ amplitude thresholds) indicate frequencies for each alteration (FreqGain,
FreqLoss) using CNApp default thresholds. Percentile 90th indicates if this region is among the top
recurrent altered regions. The last set of columns (‘Moderate’ amplitude thresholds) refers to fre-
quencies of gains and losses when amplitude thresholds are set at log2 values of 0.58 (gains) and  1
(losses). (XLSX 70 KB)
. Supplementary file 3. Comparison between significant regional peaks of amplification and deletion
identified by GISTIC2.0 and CNApp in the LIHC cohort. Statistically significant focal genomic peaks
identified by GISTIC2.0 (Q-value and residual Q-value) and the corresponding frequency reported
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by CNApp in the equivalent minor sub-cytoband genomic windows. Percentile 90th indicates if this
region is among the top recurrent altered regions. (XLSX 16 KB)
. Transparent reporting form
Data availability
Data and plots presented in the submission were generated by using our CNApp tool. Source code
and additional files can be found at GitHub (https://github.com/ait5/CNApp; copy archived at
https://github.com/elifesciences-publications/CNApp).
The following previously published datasets were used:
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Popova T, Manié E, Stoppa-Lyonnet D, Rigaill G, Barillot E, Stern MH. 2009. Genome alteration print (GAP): a
tool to visualize and mine complex Cancer genomic profiles obtained by SNP arrays. Genome Biology 10:R128.
DOI: https://doi.org/10.1186/gb-2009-10-11-r128, PMID: 19903341
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